Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tyrosine kinase inhibitor–induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors
Silvia Maifrede, Margaret Nieborowska-Skorska, Katherine Sullivan-Reed, et al.
Blood (2018) Vol. 132, Iss. 1, pp. 67-77
Open Access | Times Cited: 67

Showing 1-25 of 67 citing articles:

Regulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng Fu, Minru Liao, Rui Qin, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 487
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Charles Pottier, Margaux Fresnais, Marie Gilon, et al.
Cancers (2020) Vol. 12, Iss. 3, pp. 731-731
Open Access | Times Cited: 436
Towards precision medicine for AML
Hartmut Döhner, Andrew H. Wei, Bob Löwenberg
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 9, pp. 577-590
Closed Access | Times Cited: 212
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies
Antonella Padella, Andrea Ghelli Luserna di Rorà, Giovanni Marconi, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 71
New strategies to treat AML: novel insights into AML survival pathways and combination therapies
Ramya Nair, Alejandro Salinas-Illarena, Hanna‐Mari Baldauf
Leukemia (2020) Vol. 35, Iss. 2, pp. 299-311
Closed Access | Times Cited: 72
Peptides/Proteins Encoded by Non-coding RNA: A Novel Resource Bank for Drug Targets and Biomarkers
Song Zhu, Jizhong Wang, Yutian He, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 83
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia
Maria R. Baer, Aksinija A. Kogan, Søren M. Bentzen, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 7, pp. 1313-1322
Open Access | Times Cited: 38
BRCC36 associates with FLT3‐ITD to regulate its protein stability and intracellular signaling in acute myeloid leukemia
Jianwei Liu, Tomoya Isaji, Sachiko Komatsu, et al.
Cancer Science (2024) Vol. 115, Iss. 4, pp. 1196-1208
Open Access | Times Cited: 6
TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors
Silvia Maifrede, Bac Viet Le, Margaret Nieborowska-Skorska, et al.
Cancer Research (2021) Vol. 81, Iss. 19, pp. 5089-5101
Open Access | Times Cited: 37
Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
Rachel Abbotts, Anna J. Dellomo, Feyruz V. Rassool
Cancers (2022) Vol. 14, Iss. 11, pp. 2640-2640
Open Access | Times Cited: 27
Recent advancements in PARP inhibitors-based targeted cancer therapy
Ping‐Kun Zhou, Justin Wang, Daniel Mishail, et al.
Precision Clinical Medicine (2020) Vol. 3, Iss. 3, pp. 187-201
Open Access | Times Cited: 38
Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia
Heather C. Murray, Anoop K. Enjeti, Richard G. S. Kahl, et al.
Leukemia (2020) Vol. 35, Iss. 6, pp. 1782-1787
Open Access | Times Cited: 33
PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword
Clifford M. Csizmar, Antoine N. Saliba, Elizabeth M. Swisher, et al.
Cancers (2021) Vol. 13, Iss. 24, pp. 6385-6385
Open Access | Times Cited: 31
KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition
Liberalis Debraj Boila, Subhadeep Ghosh, Subham K. Bandyopadhyay, et al.
Leukemia (2023) Vol. 37, Iss. 4, pp. 751-764
Open Access | Times Cited: 12
Molecular Approaches to Treating Pediatric Leukemias
Michaela Kuhlen, Jan‐Henning Klusmann, Jessica I. Hoell
Frontiers in Pediatrics (2019) Vol. 7
Open Access | Times Cited: 35
Identification of Pyrrolo[2,3-d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia
Xue Yuan, Yong Chen, Wanhua Zhang, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 8, pp. 4158-4173
Closed Access | Times Cited: 34
<p>Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date</p>
Luke B. Fletcher, Sunil K. Joshi, Elie Traer
Cancer Management and Research (2020) Vol. Volume 12, pp. 151-163
Open Access | Times Cited: 30
GADD45g acts as a novel tumor suppressor, and its activation suggests new combination regimens for the treatment of AML
Dan Guo, Yangyang Zhao, Nan Wang, et al.
Blood (2021) Vol. 138, Iss. 6, pp. 464-479
Open Access | Times Cited: 27
DNA damage response defects in hematologic malignancies: mechanistic insights and therapeutic strategies
Marwan Kwok, Angelo Agathanggelou, Tatjana Stanković
Blood (2024) Vol. 143, Iss. 21, pp. 2123-2144
Closed Access | Times Cited: 3
PARG is essential for Polθ-mediated DNA end-joining by removing repressive poly-ADP-ribose marks
Umeshkumar Vekariya, Leonid Minakhin, Gurushankar Chandramouly, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment
Bac Viet Le, Paulina Podszywalow‐Bartnicka, Silvia Maifrede, et al.
Cell Reports (2020) Vol. 33, Iss. 1, pp. 108221-108221
Open Access | Times Cited: 24
Synthesis and biological evaluation of a tumor-selective degrader of PARP1
Chunlan Pu, Shirui Wang, Dan Luo, et al.
Bioorganic & Medicinal Chemistry (2022) Vol. 69, pp. 116908-116908
Closed Access | Times Cited: 16
DNA damage accumulation and repair defects in FLT3‐ITD acute myeloid leukemia: Implications for clonal evolution and disease progression
Francisco Alejandro Lagunas‐Rangel
Hematological Oncology (2022) Vol. 41, Iss. 1, pp. 26-38
Open Access | Times Cited: 16
Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon
Andrea Ghelli Luserna di Rorà, Mouna Jandoubi, Giovanni Martinelli, et al.
Molecules (2023) Vol. 28, Iss. 3, pp. 1224-1224
Open Access | Times Cited: 9
Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach
Giusj Monia Pugliese, Veronica Venafra, Valeria Bica, et al.
Leukemia (2023) Vol. 37, Iss. 5, pp. 1151-1155
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top